STOCK TITAN

Skye Bioscience - SKYE STOCK NEWS

Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.

Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.

Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.

Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.

Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech firm, will present at the Jefferies Global Healthcare Conference in NYC from June 5-6, 2024. CEO and Chair Punit Dhillon will outline the company's progress in obesity and glaucoma treatments on June 5 at 5:00 p.m. ET. A webcast of the presentation will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences
-
Rhea-AI Summary

Skye Bioscience presented new data at the ARVO 2024 Annual Meeting showcasing a novel library of synthetic cannabinoids for ocular diseases. The study focused on dry eye disease and chronic ocular pain, identifying three potential therapeutic candidates with innovative mechanisms of action. Skye aims to develop drugs modulating the endocannabinoid system to treat diverse ocular pathologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
none
-
Rhea-AI Summary

Skye Bioscience, Inc. (Nasdaq: SKYE) will present two posters at the ARVO 2024 Annual Meeting focusing on their Phase 1 study of a novel ocular drug and the development of synthetic endocannabinoid agonists. The event will take place in Seattle, Washington from May 5-9, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
Rhea-AI Summary
Skye Bioscience, a clinical-stage biotechnology company, will present at upcoming investment conferences to showcase its programs in obesity and glaucoma. CEO Punit Dhillon and team members will discuss the company's focus on developing therapeutic drugs that target the endocannabinoid system. The conferences include BTIG Obesity Day on May 8, 2024, Citizens JMP Life Sciences Conference on May 13-14, and Jefferies Global Healthcare Conference on June 5-6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
conferences
-
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) has received approval to list its common stock on the Nasdaq Global Market, moving from the OTCQB. The company's stock will trade under the ticker symbol 'SKYE', aiming to enhance visibility, attract more investors, and increase long-term shareholder value. Skye's CEO anticipates positive clinical data and the launch of a new clinical trial in the upcoming quarters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.69%
Tags
none
-
Rhea-AI Summary
Skye Bioscience, Inc. secures $40 million in financing through a private placement to fund obesity clinical development and extend operational capabilities beyond 2026. The company plans to utilize the funds to advance the development of nimacimab, a unique peripheral CB1 inhibitor for obesity treatment. Notable investors in the financing include Perceptive Advisors, Velan Capital, and Schonfeld Strategic Advisors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.95%
Tags
none
Rhea-AI Summary
Skye Bioscience, Inc. appoints Dr. Annalisa Jenkins, a seasoned pharmaceutical industry leader, to its Board of Directors. Dr. Jenkins brings over 25 years of experience in global pharmaceuticals, biotechnology, and life sciences, with a focus on developing new products across various disease areas. Her expertise in leading teams and developing strategies will aid Skye in advancing its therapeutic drugs for obesity and ocular indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
management
-
Rhea-AI Summary
Skye Bioscience, Inc. completes targeted patient enrollment ahead of schedule for its Phase 2a study of SBI-100 Ophthalmic Emulsion, a CB1 agonist for elevated intraocular pressure in glaucoma and ocular hypertension patients. Positive Phase 1 trial results indicate safety, tolerability, and efficacy potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.82%
Tags
-
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) to present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference on February 13-14, 2024, showcasing its programs in obesity and glaucoma. CEO Punit Dhillon and executive team to hold 1x1 meetings. The presentation will be webcast and available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
conferences
Rhea-AI Summary
Skye Bioscience, Inc. has announced a securities purchase agreement for the sale of common stock and pre-funded warrants, with gross proceeds of $50.25 million from a PIPE financing co-led by a life sciences-focused investor and 5AM Ventures. The financing is expected to fund operations into early 2026, including Phase 2 clinical trials for nimacimab in obesity and SBI-100 OE in glaucoma and ocular hypertension. The company is also planning a Phase 2 trial randomizing obese patients to test the efficacy of nimacimab and GLP-1R agonist in weight loss. Skye's CEO, Punit Dhillon, expressed optimism about the potential impact of CB1-modulating therapies in treating obesity and glaucoma, emphasizing the scientific validation of nimacimab's mechanism of action and the need for alternative intraocular pressure-lowering drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.03%
Tags
none
Skye Bioscience

Nasdaq:SKYE

SKYE Rankings

SKYE Stock Data

44.45M
30.58M
1.32%
84.23%
7.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO